一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (612k)
Article in Japanese

Topics Series Allergy, immunology and inflammation

Molecular-targeting drugs

Ken Ohta 

National Hospital Organization Tokyo National Hospital

ABSTRACT

A humanized anti-human IgE antibody (anti-IgE: omalizumab) was first approved for clinical use as a molecular targeting drug for asthma treatment. It has been used as a new treatment for patients with severe allergic asthma and found to be effective in about 60% of the patients. One of the developing agents following anti-IgE is a humanized anti-IL-5 antibody (mepolizumab), which showed efficacy in severe asthmatics with eosinophilia in the airways. Moreover, recombinant antibodies targeting the receptor, IL-4Ra, shared by IL-4 and IL-13 or IL-13 itself, and a humanized antibody against the IL-5 receptor have been under investigation.

KEYWORDS

Humanized anti-human IgE antibody  JGL2012  Refractory asthma  Humanized anti-IL-5 antibody  Humanized anti-IL-13 antibody 

AJRS, 3(2): 178-185, 2014

Google Scholar